DDInter1355 DDInter1676
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Oxaliplatin {u} (Compound) binds {v} (Gene) ATP7B
Oxaliplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Oxaliplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Oxaliplatin {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Oxaliplatin (Compound) binds ATP7B (Gene)
Oxaliplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Oxaliplatin may lead to a major life threatening interaction when taken with Escitalopram
Oxaliplatin may lead to a major life threatening interaction when taken with Dofetilide